|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500114203 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-09 09:48:56 |
|
注册时间: Date of Registration: |
2025-12-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国1型糖尿病患者报告结局和照护者负担研究 |
|
Public title: |
Patient-reported outcomes and caregiver burden of Type 1 diabetes in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国1型糖尿病患者报告结局和照护者负担研究 |
|
Scientific title: |
Patient-reported outcomes and caregiver burden of Type 1 diabetes in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨雪 |
研究负责人: |
翁建平 |
|
Applicant: |
Xue Yang |
Study leader: |
Jianping Weng |
|
申请注册联系人电话: Applicant telephone: |
+86 65634716 |
研究负责人电话:
Study leader's |
+86 139 0300 0303 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
Contact-US.CN@sanofi.com |
研究负责人电子邮件: Study leader's E-mail: |
wengjp@ustc.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国上海市静安区延安中路1228号嘉里中心3座19层 |
研究负责人通讯地址: |
安徽省合肥市蜀山区梅山路81号安徽医科大学知行楼A515室 |
|
Applicant address: |
19F, Tower III, Kerry Center, 1228 Middle Yan’an Road, Jing An District, Shanghai, China |
Study leader's address: |
Room A515, Zhixing Building, Anhui Medical University, No. 81 Meishan Road, Hefei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
赛诺菲(中国)投资有限公司上海分公司 |
||
|
Applicant's institution: |
Sanofi (China) Investment Co., Ltd. Shanghai Branch |
||
|
研究负责人所在单位: |
安徽医科大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Anhui Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
安医一附院科研伦审- PJ2025-09-91 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
安徽医科大学第一附属医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Review Committee of The First Affiliated Hospital of Anhui Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-31 00:00:00 | ||
|
伦理委员会联系人: |
陈奕豪 |
||
|
Contact Name of the ethic committee: |
Yihao Chen |
||
|
伦理委员会联系地址: |
安徽省合肥市蜀山区绩溪路218号 |
||
|
Contact Address of the ethic committee: |
No. 218, Jixi Road, Shushan District, Hefei City, Anhui Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 551 6292 3102 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
安徽医科大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Anhui Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽省合肥市蜀山区绩溪路218号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 218, Jixi Road, Shushan District, Hefei City, Anhui Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
赛诺菲(中国)投资有限公司上海分公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sanofi (China) Investment Co., Ltd. Shanghai Branch |
||||||||||||||||||||||
|
研究疾病: |
1型糖尿病 |
||||||||||||||||||||||
|
Target disease: |
Type 1 diabetes |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
主要目的: 1.描述成人和儿童青少年1型糖尿病 (T1D)患者的健康相关生活质量 (HRQoL); 2.描述儿童青少年T1D患者照护者的HRQoL; 3.描述成人 T1D 患者和儿童青少年青少年患者照护者的工作生产力损失; 次要目的: 1.探究人口统计学特征及其他变量对患者的 HRQoL与照护者负担的影响; 2.生成T1D患者及照护者的负效用值和工作生产力损失值. |
||||||||||||||||||||||
|
Objectives of Study: |
Primary objectives: 1. To describe the health-related quality of life (HRQoL) of adult and pediatric/adolescent patients with type 1 diabetes (T1D); 2. To describe the HRQoL of caregivers of pediatric/adolescent T1D patients; 3. To describe work productivity loss in adult T1D patients and caregivers of pediatric/adolescent patients. Secondary objectives: 1. To explore the impact of demographic characteristics and other variables on patients' HRQoL and caregiver burden; 2. To generate disutility values and work productivity loss values for T1D patients and caregivers. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
成人T1D患者纳入标准: 1.年龄18岁及以上; 2.已确诊为T1D; 3.能够阅读并理解简体中文; 4.愿意提供知情同意; 5.愿意完成15至20分钟的问卷; 儿童青少年T1D患者纳入标准: 1.年龄在8岁(包含)至18岁(不包含)之间; 2.已确诊为T1D; 3.能够阅读并理解简体中文; 4.愿意提供知情同意; 5.愿意完成5至10分钟的问卷; 儿童青少年T1D患者照护者纳入标准: 1.年龄18岁及以上; 2.为符合上述纳入标准的儿童青少年患者的父母照护者; 3.能够阅读并理解简体中文; 4.愿意提供知情同意; 5.愿意完成15至20分钟的问卷. |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria for adult T1D patients: 1. Aged 18 years or older; 2. Diagnosed with T1D; 3. Able to read and understand Simplified Chinese; 4. Willing to provide informed consent; 5. Willing to complete a 15 to 20-minute questionnaire. Inclusion criteria for pediatric and adolescent T1D patients: 1. Aged 8 years (inclusive) to 18 years (exclusive); 2. Diagnosed with T1D; 3. Able to read and understand Simplified Chinese; 4. Willing to provide informed consent; 5. Willing to complete a 5 to 10-minute questionnaire. Inclusion criteria for caregivers of pediatric and adolescent T1D patients: 1. Aged 18 years or older; 2. Parent or caregiver of a pediatric or adolescent patient meeting the above inclusion criteria; 3. Able to read and understand Simplified Chinese; 4. Willing to provide informed consent; 5. Willing to complete a 15 to 20-minute questionnaire. |
||||||||||||||||||||||
|
排除标准: |
目前参与T1D相关的临床试验 |
||||||||||||||||||||||
|
Exclusion criteria: |
Participation in a clinical trial for T1D |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-12-20 00:00:00至 To 2026-02-11 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-12-20 00:00:00 至 To 2026-02-11 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF和EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |